Private equity group Apax Funds will buy Gerresheimer’s 15 manufacturing sites for primary plastic packaging in nine countries and Centor’s U.S. production site.
The long-term agreement announced by the CDMO reserves half of its Yokohama facility’s mammalian manufacturing capacity for five commercial biologics programs.
The teaming combines biologics manufacturing and formulation development expertise to support bispecific antibodies, fusion proteins, and other therapies.
The companies will combine antibody discovery, AI-enabled research, manufacturing, and commercialization to advance biologics for oncology and immune-mediated diseases.
Pharmaceutical construction projects face rising delays and costs. Learn how early supplier engagement, smarter coating strategies and expert field support can protect schedules...
Reactive hiring can't keep pace with GLP-1 demand. Discover why surge-and-scramble staffing fails specialty pharma fulfillment — and how a BPO workforce model builds the flexibility...
Join this webinar to discover how data orchestration and Digital Threads provide the trusted context needed to scale Industrial AI, accelerate Smart Manufacturing, and drive ...
Both CRDMOs were accused of ties to China’s government, yet only WuXi AppTec was recently added to the Pentagon list of “Chinese military companies” operating in the U.S.
As global and domestic pressures mount, Japanese drugmakers are looking to improve development timelines, manufacturing execution, and operational efficiency.
Big Pharma and contract development and manufacturing organizations are making large capital expenditures to build infrastructure supporting the wildly popular medications.
The Indian drugmaker reported certain batches were out of specification due to an issue associated with the active pharmaceutical ingredient used in the product.
As priorities evolve, single-use technologies are enabling more flexible facilities, hybrid manufacturing strategies, and the next generation of biopharmaceutical production.
The pharmaceutical giant is leveraging artificial intelligence to scale production and optimize the efficiency of operations to meet high demand for its medicines.
Bureau of Labor Statistics forecasts pharmaceutical manufacturing will add nearly 19,000 production jobs, ranking among the fastest-growing industries.
The integration of chemical engineering into process development has transformed how companies scale, control, and optimize manufacturing for a new generation of therapies.
The draft guidance allows developers to leverage chemistry, manufacturing and controls data, as well as nonclinical and clinical information from other relevant products.
Faced with the increasing complexity of peptide programs, Japan’s drugmakers are turning to outsourcing in preclinical and early stages, contends Neuland Laboratories.
AI is helping life sciences manufacturers improve uptime, PM effectiveness, calibration planning, and reliability analysis. See where practical AI adds value in GMP asset management...
Software platforms can seamlessly integrate with emerging technologies to unlock efficiencies, strengthen sustainability and enable proactive prevention of disruptions.
Built-in ability to meet data integrity standards should be a central focus when selecting control systems and manufacturing execution systems for pharma manufacturing
As one of seven companies picked for the pilot, the integrated development and manufacturing organization says regulatory engagement cuts commercialization risk.
The agency selected contract manufacturers Cellares and Fujifilm Biotechnologies, as well as Big Pharma drugmakers Eli Lilly and Regeneron, for the pilot’s initial cohort.
The fill-finish facility in Bloomington, formerly owned by Catalent, was cited for eight observations including persistent contamination and quality systems deficiencies.
Industry stakeholders support the agency’s effort to engage manufacturers earlier in facility development, but uncertainty remains on how the program will be implemented.
Kansas-Missouri’s $34 million will translate biologic discoveries into U.S. production, while Virginia’s $16 million will develop and scale pharmaceutical manufacturing.
The legislation aims to increase visibility of foreign supply sources amid what they warn is a “growing foothold” in domestic pharmaceutical manufacturing.
Chinese biopharma companies lead when it comes to manufacturing scale, CDMO capacity, and raw materials, according to analyses from the Cure Innovation Index.
